AgeX Therapeutics Announces Reduction in Projected Cash Expenditures

AgeX plans to continue to pursue its licensing and collaboration strategy for its two primary technology platforms, UniverCyte immunotolerance technology, and PureStem cell derivation and manufacturing technology.